In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Premature cardiovascular diseases and comorbidity in outpatient and hospital practice: data of registries RECVASA and RECVASA-CLINICA

Session Poster Session 2

Speaker Elena Andreenko

Congress : ESC Preventive Cardiology (Formerly EuroPrevent) 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session
  • FP Number : P542

Authors : MM Lukiyanov (Moscow,RU), EY Andreenko (Moscow,RU), OM Drapkina (Moscow,RU), IS Yavelov (Moscow,RU), SY Martsevich (Moscow,RU), SS Yakushin (Ryazan,RU), AN Vorobyev (Ryazan,RU), AN Kozminsky (Ryazan,RU), KA Moseichuk (Ryazan,RU), KG Pereverzeva (Ryazan,RU), EA Pravkina (Ryazan,RU), EY Okshina (Moscow,RU), VG Klyashtorny (Moscow,RU), EV Kudryashov (Moscow,RU), SA Boytsov (Moscow,RU)

MM Lukiyanov1 , EY Andreenko1 , OM Drapkina1 , IS Yavelov1 , SY Martsevich1 , SS Yakushin2 , AN Vorobyev2 , AN Kozminsky2 , KA Moseichuk2 , KG Pereverzeva2 , EA Pravkina2 , EY Okshina1 , VG Klyashtorny1 , EV Kudryashov1 , SA Boytsov3 , 1National Research Center for Preventive Medicine - Moscow - Russian Federation , 2Ryazan State Medical University - Ryazan - Russian Federation , 3National Medical Research Center for Cardiology - Moscow - Russian Federation ,


Aim. To estimate age characteristics of premature cardiovascular diseases (CVD) and comorbidities in real outpatient and hospital practice.

Methods. Patients with hypertension, coronary artery disease, chronic heart failure, atrial fibrillation and stroke were enrolled in outpatient RECVASA registry in Ryazan region (n=3690) and hospital RECVASA-CLINICA registry in Moscow region of Russia (n=8954). Age of patients was 66.1±12.9 and 66.6±12.7 years, respectively. The first and the second deciles of age distribution were used for definition of younger groups with premature CVD and cardiovascular (CV) comorbidity, premature myocardial infarction (MI) and stroke.

Results. Age of patients in the first decile groups in outpatient and hospital registries was not older than 50 and 51 years, respectively, and age of the second decile groups was 51-55 and 52-57 years, respectively (premature CVD criteria). The mean number of CVD in patients of the first decile group was 1.6±0.4 and 1.5±0.6 and it was significantly more in the second decile group – 2.1±0.5 and 1.9±0.7 (p<0.05). CV comorbidity in patients of the first and the second decile groups was diagnosed in RECVASA registry in 42.2% and 63.6% of cases (p<0.0001) and in RECVASA-CLINICA registry – in 36.0% and 61.2% (p<0.0001). So, the group of the first decile of age distribution is preferable for estimation of premature comorbidity than group of the second decile in which an incidence of CV comorbidity was 1.5 and 1.7 times more in two analyzed registries. The maximal age of the first decile of CV patients with premature comorbidity (=2 CVD) was 54 and 55 years, with premature pronounced comorbidity (=3 CVD) – 56 and 57 years. Age of patients with history of MI in the first decile groups in outpatient and hospital registries was not older than 55 and 53 years, with history of stroke – not older than 57 years in both. The most young groups of patients in RECVASA and RECVASA-CLINICA registries were: below 40 years – 2.7% and 3.1% of cases; 40-44 years – 2.0% and 2.2%; 45-49 years – 4.7% and 3.7%. So, age 40 and older was registered in quite all cases (97.3% and 96.9%).

Conclusions. RECVASA and RECVASA-CLINICA registries revealed similar age criteria of premature CV pathology: CVD - not older than 50 and 51 years (in the first place from 40 to 49 years); premature CV comorbidity - not older than 54 and 55 years, respectively; premature MI – not older than 55 and 53 years; premature stroke - than 57 years in both. So, for premature CV comorbidity, history of premature MI and stroke the maximal age of the first decile was 3-7 years older than for premature CVD. It is optimal to begin an active primary preventive measures to delay the development of CVD and CV comorbidity in patients aged below 50-51 years both in outpatient and hospital settings, below 53-57 years – for primary/secondary prevention of CV comorbidity onset or progression and for primary prevention of MI and stroke.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are